Our study demonstrates that PR MS patients exhibit higher percentages of antigen-specific CD8+ T cells and CD107a-producing T cells, suggesting that enhanced cytotoxic activity may compensate for their deficit in antibody production. The gene discussed is CD8A; the disease is myeloid sarcoma.